All In Biotech

Drug Trial Radar · NCT06508658

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 379 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

379

Actual

Start

Aug 13, 2024

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R DLBCL will be enrolled in approximately 165 sites across the world. Participants in arm A will receive subcutaneous (SC) injections of epcoritamab plus oral lenalidomide capsules (E-Len) for up to 12 cycles (each cycle is 28 days). Participants in arm B will receive intravenously (IV) infused R-GemOx for up to 4 cycles (each cycle is 28 days). Participants in arm C will receive SC injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • EpcoritamabDrug

    Subcutaneous Injection

  • RituximabDrug

    Intravenous (IV) Infusion

  • LenalidomideDrug

    Oral Capsule

  • OxaliplatinDrug

    IV Infusion

  • GemcitabineDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm A vs Arm B: Progression-Free Survival (PFS)Time frame: Up to 4 Years

Locations

176 sites in 28 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center /ID# 273338

    Duarte, California

  • Valkyrie Clinical Trials /ID# 269935

    Los Angeles, California

  • Desert Regional Medical Center /ID# 272437

    Palm Springs, California

  • Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823

    Golden, Colorado

  • City Of Hope - Atlanta. /ID# 273092

    Newnan, Georgia

  • Rush University Medical Center /ID# 242103

    Chicago, Illinois

  • City Of Hope - Chicago /ID# 274430

    Zion, Illinois

  • Northwest Cancer Center - Dyer Clinic /ID# 269787

    Dyer, Indiana

  • Cancer Center of Kansas - Wichita /ID# 270117

    Wichita, Kansas

  • University of Kentucky Chandler Medical Center. /ID# 242087

    Lexington, Kentucky

  • University of Maryland, Baltimore /ID# 242216

    Baltimore, Maryland

  • Henry Ford Hospital /ID# 266446

    Detroit, Michigan

  • Gulfport Memorial Hospital /ID# 268104

    Gulfport, Mississippi

  • New York Medical College /ID# 265799

    Valhalla, New York

  • East Carolina University - Brody School of Medicine /ID# 242227

    Greenville, North Carolina

  • Thompson Cancer Survival Ctr /ID# 242149

    Knoxville, Tennessee

  • Community Cancer Trials Of Utah /ID# 271715

    Ogden, Utah

  • Utah Cancer Specialists - Salt Lake City /ID# 268603

    Salt Lake City, Utah

  • Veterans Affairs Medical Center - Salt Lake City /ID# 265329

    Salt Lake City, Utah

  • Hospital Universitario Austral /ID# 242791

    Pilar, Buenos Aires, Argentina

  • Fundaleu /Id# 242789

    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina

  • Instituto Alexander Fleming /ID# 263804

    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina

  • Canberra Hospital /ID# 265312

    Garran, Australian Capital Territory, Australia

  • Royal Prince Alfred Hospital /ID# 263242

    Sydney, New South Wales, Australia

  • Wollongong Hospital /ID# 244646

    Wollongong, New South Wales, Australia

  • Toowoomba Hospital /ID# 263243

    Toowoomba, Queensland, Australia

  • Monash Health - Monash Medical Centre /ID# 262783

    Clayton, Victoria, Australia

  • Royal Perth Hospital /ID# 243790

    Perth, Western Australia, Australia

  • Universitair Ziekenhuis Brussel /ID# 242574

    Jette, Brussels Capital, Belgium

  • Centre Hospitalier Epicura - Hornu /ID# 265148

    Boussu, Hainaut, Belgium

  • Universite Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 242565

    Yvoir, Namur, Belgium

  • Universitair Ziekenhuis Leuven /ID# 246671

    Leuven, Vlaams-Brabant, Belgium

  • AZ-Delta. /ID# 264740

    Roeselare, West-Vlaanderen, Belgium

  • Hospital Alemao Oswaldo Cruz /ID# 247418

    São Paulo, Brazil

  • Instituto D'Or de Pesquisa e Ensino - Regional Sao Paulo /ID# 263944

    São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 242425

    São Paulo, Brazil

  • Hospital Sao Rafael /ID# 262949

    Salvador, Estado de Bahia, Brazil

  • Hospital Erasto Gaertner /ID# 264049

    Curitiba, Puerto Rico, Brazil

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto /ID# 264045

    Ribeirão Preto, São Paulo, Brazil

  • UMHAT Sveti Georgi /ID# 242905

    Plovdiv, Bulgaria

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.